Nicotinamide and innate immunity in patients with bronchiectasis
Enhanced innate immunity and killing of respiratory pathogens by nicotinamide in patients with bronchiectasis
Dr Conroy Wong, Middlemore Hospital
8 participants
Jul 1, 2013
Interventional
Conditions
Summary
We aim to determine the dose of nicotinamide (NAM) that achieves a serum level of at least 1 mM, and also to assess the effect of nicotinamide on upregulation of neutrophil function and bacterial killing in both patients with bronchiectasis and healthy volunteers. We want to prove if nicotinamide may augment neutrophil function and enhance the killing of respiratory pathogens in patients with bronchiectasis
Eligibility
Inclusion Criteria9
- Male or female aged between 18 to 80 years old
- able to provide written consent form
- Patients with confirmed bronchiectasis by High resolution
- CT scan
- history of at least one pulmonary exacerbation in the
- past 12 months
- healthy volunteers should be never smoker with no
- underlying acute or chronic medical conditions and not
- taking regular medications
Exclusion Criteria6
- Pregnant or lactating women
- patients with significant medical conditions other than
- bronchiectasis
- patients with significant abnormal liver function or with
- liver cirrhosis
- patients with a history of non-adherence with medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will take oral nicotinamide capsules twice daily in one of the 4 dosage groups for a total duration of 2 weeks:- 1500mg twice daily 2000mg twice daily 2500mg twice daily 3000mg twice daily compliance will be ensured by capsules count at every follow up visit, blood will be collected for nicotinamide level prior to start of nicotinamide taking and then at every follow up visit.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613000699763